Lyell Immunopharma, Inc. (LYEL) Stock Price & Analysis

Lyell Immunopharma, Inc. (LYEL) rose 0.35% to USD 14.37 as of September 8, 2026 at 06:23 UTC, according to Nexqual real-time market data.

LYEL last closed at USD 14.37; the session ranged USD 13.92–14.68 on volume of 54,065 shares. Market capitalization is —, with a 52-week range of USD 11.47–45 (NMS). Source: Nexqual, September 8, 2026 at 06:23 UTC.

Key Statistics (as of September 8, 2026 at 06:23 UTC)

Technical Analysis (LYEL)

Nexqual's technical model rates LYEL "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 06:23 UTC.

From Lyell Immunopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Our research scientists are also developing next-generation CAR T-cell product candidates for additional solid tumor indications enhanced with our anti-exhaustion and additional arming technologies and manufactured with our proprietary protocols.
• We continue to invest in earlier stage cell therapy research and development utilizing our proprietary technologies.
• Epi-R Manufacturing Protocol Epi‑R is our proprietary ex vivo manufacturing protocol that is designed to generate populations of stemlike T cells with reduced exhaustion and improved proliferation and antitumor activity.
• Our nonclinical research activities explore stacking our proprietary anti-exhaustion technologies with these additional approaches via the expression of novel chimeric proteins and vector design to generate fully-armed CAR T-cell product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:23 UTC. This page is informational and not investment advice.